FBRX shareholders should tender shares into the offer at $77.00, which represents a significant premium. The key risk to closing is HSR antitrust review, though the transaction is not subject to a financing condition. Monitor for any competing bids during the go-shop period and the Schedule 14D-9 filing for the fairness opinion details.
Price Chart
Executive Summary
Forte Biosciences (FBRX) has entered into a definitive merger agreement to be acquired by argenx (ARGX) for $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. The transaction will proceed via a tender offer followed by a merger under Section 251(h) of the DGCL, with the Forte board unanimously recommending the offer. The deal provides a substantial premium to recent trading levels and is expected to close in Q3 2026, funded entirely from argenx's cash on hand, with no financing condition.
Key Financial Metrics
Key Facts
- argenx to acquire Forte Biosciences for $77.00 per share in cash, total equity value ~$2.2 billion
- Premium of approximately 86% to Forte's VWAP since reporting positive Phase 1b vitiligo data on July 9, 2026
- Transaction structured as a tender offer for a majority of shares, followed by a merger under DGCL Section 251(h)
- Forte's lead program is FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease
- Deal expected to close in Q3 2026, subject to regulatory approval (HSR) and minimum tender condition of >50% of shares
- Termination fee of $65 million payable by Forte under specified circumstances
- Support agreements in place with directors and executive officers holding ~1% of outstanding shares
- Transaction not subject to a financing condition; funded entirely from argenx's cash on hand
Financial Impact
Total equity value of approximately $2.2 billion, or $77.00 per share in cash
Risk Factors
- Potential competing acquisition proposal triggering a termination fee
- Regulatory delay or failure to obtain HSR clearance
- Stockholder litigation challenging the transaction
- Failure to meet the minimum tender condition of >50% of shares
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-316766 |
| Document: d31466dex101.htm | 0001193125-26-316766 |
| Document: d31466d8k.htm | 0001193125-26-316766 |
| Document: d31466dex991.htm | 0001193125-26-316766 |
| Document: 0001193125-26-316766-index-headers.html | 0001193125-26-316766 |
| Document: 0001193125-26-316766-index.html | 0001193125-26-316766 |
| Document: 0001193125-26-316766.txt | 0001193125-26-316766 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | EFFECT | $76.99 awaiting T+1 | awaiting T+1 | — | — |
Sep 2, 2026 4w ago | EFFECT | $76.99 awaiting T+1 | awaiting T+1 | — | — |
Aug 27, 2026 5w ago | 25-NSE | $76.99 $76.99 | · 0.00% | ▼ −0.23% | — |
Jul 27, 2026 9w ago | 8-K | $76.50 $76.65 | ▲ +0.20% | ▼ −0.04% | — |
Jun 11, 2026 16w ago | EFFECT | $17.40 $17.56 | ▼ −0.92% | ▼ −0.38% | — |
Jun 6, 2026 16w ago | S-3/A | $15.67 $17.00 | ▼ −8.49% | ▼ −8.78% | — |
Jun 2, 2026 17w ago | S-3 | $17.00 $16.69 | ▲ +1.82% | ▲ +2.22% | — |
Jun 2, 2026 17w ago | 8-K | $17.00 $16.69 | ▼ −1.82% | ▼ −2.23% | — |
May 14, 2026 20w ago | 8-K | $23.11 $20.97 | ▼ −9.26% | ▼ −9.20% | — |
Apr 9, 2026 25w ago | 8-K | $33.90 $35.09 | ▲ +3.51% | ▲ +3.57% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access